AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26810403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate (IngMeb) 0.015% daily for 3 days followed by clobetasol propionate (0.05%) twice daily for 4 days
Number of subjects: 0
Study 26810403 — intervention group
Group type: COMPARATOR
Intervention: Ingenol mebutate (IngMeb) 0.015% daily for 3 days
Number of subjects: 0
Study 25260632 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly16+Glu27 haplotype
Number of subjects: 71
Study 25260632 — intervention group
Group type: EXPERIMENTAL
Intervention: Arg16+Gln27 haplotype
Number of subjects: 71
Study 25260632 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress trial
Number of subjects: 71
Study 25260632 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip and forearm vasodilation
Number of subjects: 71
Study 25260632 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB2 density
Number of subjects: 71
Study 22270198 — intervention group
Group type: EXPERIMENTAL
Intervention: A/BPO and DCN followed by A/BPO
Number of subjects: 0
Study 22270198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle and DCN followed by A/BPO
Number of subjects: 0
Study 22270198 — intervention group
Group type: EXPERIMENTAL
Intervention: A/BPO and DCN followed by vehicle
Number of subjects: 0
Study 22270198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle and DCN followed by vehicle
Number of subjects: 0
Study 22270198 — intervention group
Group type: COMPARATOR
Intervention: DCN and vehicle (initial treatment)
Number of subjects: 0
Study 20004061 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane (Biomembrane) dressing
Number of subjects: 46
Study 20004061 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane membrane (Tegaderm) dressing
Number of subjects: 46
Study 17928105 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (20 mg/day) plus placebo
Number of subjects: 0
Study 17928105 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day) plus pindolol (7.5 mg/day)
Number of subjects: 0
Study 15955042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sydenham's chorea (SC) patients
Number of subjects: 220
Study 15955042 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatic fever (RF) patients without neurological symptoms
Number of subjects: 220
Study 15955042 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 220
Study 12776276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C, 500 mg, three times a week
Number of subjects: 63
Study 12776276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10385721 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg)
Number of subjects: 18
Study 10385721 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg)
Number of subjects: 18
Study 10385721 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 18
Study 8721799 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer staff performing recruitment tasks (mailings, telephoning, clerical work)
Number of subjects: 12
Study 8721799 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer staff
Number of subjects: 12
Study 1513858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 0
Study 1513858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6148617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous followed by oral propranolol
Number of subjects: 735
Study 6148617 — intervention group
Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 735
Study 29452024 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of complete recovery
Number of subjects: 252
Study 29558811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-based activity tracking devices
Number of subjects: 32
Study 29558811 — intervention group
Group type: COMPARATOR
Intervention: Wrist-based activity tracking devices
Number of subjects: 32
Study 29558811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of devices
Number of subjects: 32
Study 26977625 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-150 mg/day for 4 weeks)
Number of subjects: 40
Study 26977625 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-150 mg/day for 4 weeks) plus cerebrolysin (20 i/v infusions during 4 weeks, 20.0 ml in 100 ml isotonic NaCl solution)
Number of subjects: 40
Study 26977625 — intervention group
Group type: COMPARATOR
Intervention: Control group (Venlafaxine alone)
Number of subjects: 40
Study 24284361 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs17249141
Number of subjects: 1860
Study 24284361 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs rs2738447, rs14158, rs2738465, rs3180023
Number of subjects: 1860
Study 22432114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate therapy (case subjects, n = 321)
Number of subjects: 1061
Study 22432114 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate control subjects (n = 175)
Number of subjects: 1061
Study 22432114 — intervention group
Group type: COMPARATOR
Intervention: Placebo control subjects (n = 565)
Number of subjects: 1061
Study 19023095 — intervention group
Group type: EXPERIMENTAL
Intervention: TEMPiS intervention (specialized stroke wards, continuous medical education, telemedical consultation)
Number of subjects: 3060
Study 19023095 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (without specialized stroke facilities or telemedical support)
Number of subjects: 3060
Study 17804936 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group intervention (6 sessions over 2 weeks)
Number of subjects: 36
Study 17804936 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group intervention
Number of subjects: 36
Study 17804936 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 15100508 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting Tl gated SPECT studies
Number of subjects: 30
Study 15100508 — intervention group
Group type: EXPERIMENTAL
Intervention: Redistribution Tl gated SPECT studies
Number of subjects: 30
Study 15100508 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual wall thickening assessment
Number of subjects: 30
Study 15100508 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated wall thickening assessment
Number of subjects: 30
Study 12297844 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN alfa‐2b 3 times per week plus ribavirin 1,000 mg/d for 12 months (Group A)
Number of subjects: 295
Study 12297844 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU IFN alfa‐2b 3 times per week plus ribavirin for 12 months (Group B)
Number of subjects: 295
Study 12297844 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN alfa‐2b 3 times per week plus ribavirin for 6 months (Group C)
Number of subjects: 295
Study 12297844 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU IFN alfa‐2b 3 times per week plus ribavirin for 6 months (Group D)
Number of subjects: 295
Study 12297844 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A and B (3 MU and 5 MU for 12 months) in patients with genotype 1 and 4
Number of subjects: 295
Study 12297844 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A, B, C, D in patients with genotype 2 and 3
Number of subjects: 295
Study 9613306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 52
Study 9613306 — intervention group
Group type: COMPARATOR
Intervention: Mask
Number of subjects: 52
Study 9613306 — intervention group
Group type: COMPARATOR
Intervention: Mouthpiece with nose clip
Number of subjects: 52
Study 8134206 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg intravenously at 6 to 12 postnatal hours and every 24 hours for two more doses)
Number of subjects: 431
Study 8134206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 8134206 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 431
Study 2552600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium, 4 mg four times daily by inhalation
Number of subjects: 89
Study 2552600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 1091305 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosleep (ES) treatment; five half-hour sessions; duration not specified.
Number of subjects: 0
Study 1091305 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study 31169723 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy (A group) with 5 semi-permanent needles inserted in both ears at specific points.
Number of subjects: 53
Study 31169723 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group) with 5 small round patches of adhesive pads positioned bilaterally at the same points.
Number of subjects: 53
Study 29275795 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical acupuncture with placebo tablet
Number of subjects: 157
Study 29275795 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture with placebo tablet
Number of subjects: 157
Study 29275795 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture with ibuprofen
Number of subjects: 157
Study 25239086 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory rehabilitation intervention
Number of subjects: 24
Study 23992025 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 540
Study 23992025 — intervention group
Group type: COMPARATOR
Intervention: Control (without capnography)
Number of subjects: 540
Study 21925346 — intervention group
Group type: EXPERIMENTAL
Intervention: pantethine (600 mg/d for weeks 1-8, then 900 mg/d for weeks 9-16)
Number of subjects: 120
Study 21925346 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 19905885 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 627
Study 19905885 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 627
Study 16773951 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (SSRIs)
Number of subjects: 4487
Study 16773951 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (non-specific)
Number of subjects: 4487
Study 16773951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4487
Study 12957419 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/day for four weeks)
Number of subjects: 115
Study 12957419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 12957419 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 115
Study 12957419 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and Placebo
Number of subjects: 115
Study 11116409 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 42
Study 11116409 — intervention group
Group type: COMPARATOR
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 42
Study 8644885 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention allocated to verbal stimulus during addition problems; varying difficulty and instructions.
Number of subjects: 0
Study 8644885 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct test of recognition memory; assessed after addition problems.
Number of subjects: 0
Study 8644885 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect test of repetition priming in lexical decision; assessed at lags of 0, 1, or 8 intervening trials.
Number of subjects: 0
Study 1380989 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine alone
Number of subjects: 98
Study 1380989 — intervention group
Group type: COMPARATOR
Intervention: Eflornithine- mitoguazone
Number of subjects: 98
Study 6150725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 8
Study 6150725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31540876 — intervention group
Group type: EXPERIMENTAL
Intervention: Saba shielding (1 T)
Number of subjects: 20
Study 31540876 — intervention group
Group type: EXPERIMENTAL
Intervention: Saba shielding (3 T)
Number of subjects: 20
Study 31540876 — intervention group
Group type: EXPERIMENTAL
Intervention: Saba shielding (90% Cu, 10% Bi)
Number of subjects: 20
Study 31540876 — intervention group
Group type: COMPARATOR
Intervention: Bismuth shielding (100% Bi)
Number of subjects: 20
Study 31812185 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of allergenic foods
Number of subjects: 0
Study 28470157 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling program based on goal attainment theory (8 sessions, once a week, 45 minutes each)
Number of subjects: 44
Study 25855628 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg prednisone daily for 5 days
Number of subjects: 311
Study 25855628 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg prednisone daily for 14 days
Number of subjects: 311
Study 25855628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 25855628 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment (both 5 and 14 days)
Number of subjects: 311
Study 22763799 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono-phosphate (MP)
Number of subjects: 14
Study 22763799 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-phosphate (PP)
Number of subjects: 14
Study 22763799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21700757 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D (Group 1: 26 patients)
Number of subjects: 73
Study 21700757 — intervention group
Group type: COMPARATOR
Intervention: CRT-D (Group 2a: 23 patients)
Number of subjects: 73
Study 21700757 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (Group 2b: 21 patients)
Number of subjects: 73
Study 18078906 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material containing 300 mg iodine/mL (Iomeprol 300) injected at a rate of 1 g of iodine/second
Number of subjects: 60
Study 18078906 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material containing 400 mg iodine/mL (Iomeprol 400) injected at a rate of 1 g of iodine/second
Number of subjects: 60
Study 18078906 — intervention group
Group type: EXPERIMENTAL
Intervention: Including patient body weight in the analysis
Number of subjects: 60
Study 16610157 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (n = 26)
Number of subjects: 55
Study 16610157 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition (n = 29)
Number of subjects: 55
Study 12826971 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine scalp infiltration
Number of subjects: 41
Study 12826971 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2 microg/kg intravenous)
Number of subjects: 41
Study 11596665 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide combination (ACE inhibitor-diuretic)
Number of subjects: 10000
Study 11596665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive gliclazide MR-based glucose control regimen
Number of subjects: 10000
Study 11596665 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for perindopril-indapamide
Number of subjects: 10000
Study 11596665 — intervention group
Group type: COMPARATOR
Intervention: Usual guidelines-based therapy for glucose control
Number of subjects: 10000
Study 9303949 — intervention group
Group type: EXPERIMENTAL
Intervention: Punishment
Number of subjects: 0
Study 9303949 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 9303949 — intervention group
Group type: EXPERIMENTAL
Intervention: Punishment and Control
Number of subjects: 0
Study 8285750 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk feeds supplemented with Lactobacillus GG 10(8) colony forming units twice a day for two weeks
Number of subjects: 20
Study 8285750 — intervention group
Group type: COMPARATOR
Intervention: Milk feeds
Number of subjects: 20
Study 3578848 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 25
Study 3578848 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% morphine
Number of subjects: 25
Study 3578848 — intervention group
Group type: COMPARATOR
Intervention: Saline (30 ml perineurally and 1 ml intramuscularly) with 6 mg morphine
Number of subjects: 25
Study 30123060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (2000 mg/d vitamin C; 1400 U/d vitamin E)
Number of subjects: 18
Study 27062334 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-concordant therapy
Number of subjects: 111
Study 27062334 — intervention group
Group type: COMPARATOR
Intervention: Empiric therapy (sulbactam/ampicillin or ceftriaxone)
Number of subjects: 111
Study 25023798 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (1 mg/kg of BW) administered orally at loading (d 0), unloading (d 1), and daily from d 2 to 7 of feedlot receiving (MEL)
Number of subjects: 84
Study 25023798 — intervention group
Group type: COMPARATOR
Intervention: Lactose monohydrate (1 mg/kg of BW) administered orally (TRANS)
Number of subjects: 84
Study 25023798 — intervention group
Group type: COMPARATOR
Intervention: Lactose monohydrate (1 mg/kg of BW) administered orally (CON)
Number of subjects: 84
Study 25023798 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (1 mg/kg of BW) administered orally (MEL)
Number of subjects: 84
Study 23467862 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections prior to cast treatment
Number of subjects: 47
Study 23467862 — intervention group
Group type: COMPARATOR
Intervention: Below-the-knee casts (control)
Number of subjects: 47
Study 23467862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (cast treatment and botulinum toxin A)
Number of subjects: 47
Study 20495802 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference screws (direct form)
Number of subjects: 60
Study 20495802 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcondylar cross-pin screw (from a distance)
Number of subjects: 60
Study 18572334 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg once weekly
Number of subjects: 63
Study 18572334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16598518 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg bid
Number of subjects: 59
Study 16598518 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg bid
Number of subjects: 59
Study 12694145 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal paracetamol 1000 mg four times daily
Number of subjects: 78
Study 12694145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 12694145 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal paracetamol 1000 mg
Number of subjects: 78
Study 12694145 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher paracetamol concentration
Number of subjects: 78
Study 10894579 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) in patients with AMI (Group I)
Number of subjects: 480
Study 10894579 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) in patients without AMI (Group III)
Number of subjects: 480
Study 10894579 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II) - patients with AMI without DRE
Number of subjects: 480
Study 9552820 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite inlays
Number of subjects: 45
Study 9552820 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite fillings
Number of subjects: 45
Study 9552820 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall restorations (both inlays and fillings)
Number of subjects: 45
Study 1590051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation (18 knees)
Number of subjects: 33
Study 1590051 — intervention group
Group type: COMPARATOR
Intervention: Cementless fixation (15 knees)
Number of subjects: 33
Study 1590051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented and cementless fixation
Number of subjects: 33
Study 3812055 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician advice plus nicotine chewing gum (NCG) prescription
Number of subjects: 289
Study 3812055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (NCG) users
Number of subjects: 289
Study 3812055 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term NCG users (greater than 20 days)
Number of subjects: 289
Study 3812055 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term NCG users
Number of subjects: 289
Study 3812055 — intervention group
Group type: COMPARATOR
Intervention: No advice group
Number of subjects: 289
Study 29669736 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored letter intervention
Number of subjects: 2014
Study 29669736 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2014
Study 27245219 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic tennis elbow release (ECRB release)
Number of subjects: 0
Study 27245219 — intervention group
Group type: COMPARATOR
Intervention: Sham lateral portal (no ECRB release)
Number of subjects: 0
Study 25927224 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 982
Study 22170177 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium infusion within 4 days (Group I)
Number of subjects: 30
Study 22170177 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 30
Study 16003061 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic and disease-specific HRQOL questionnaires (SF-36 and SGRQ)
Number of subjects: 73
Study 16003061 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Component Score of SF-36
Number of subjects: 73
Study 16003061 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Component Score of SF-36 and SGRQ scores
Number of subjects: 73
Study 16003061 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance measures
Number of subjects: 73
Study 16003061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung spirometry tests
Number of subjects: 73
Study 16003061 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between forced expiratory volume in 1 sec and physical function domain of SF-36
Number of subjects: 73